MarketPulse

BrainStorm Cell Therapeutics

2 articles
BenzingaBenzinga··Prnewswire

BrainStorm Appoints Former FDA Official as Board Bolsters ALS Trial Push

BrainStorm appoints former FDA Associate Commissioner Peter Pitts to board ahead of Phase 3b ALS trial launch with historic FDA Special Protocol Assessment.
BCLIstem cell therapyNurOwn
BenzingaBenzinga··Prnewswire

BrainStorm Charts Recovery Path With $2M Funding as NurOwn Advances to Pivotal ALS Trial

BrainStorm Cell Therapeutics reported $10.3M net loss for 2025 while securing $2M financing and advancing NurOwn into Phase 3b ALS study following FDA clearance.
BCLIfinancial resultsprivate placement